Highfields Capital Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Highfields Capital Management’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-239,232	Closed	-$30.2M	–	45
2018 Q3	$30.2M	Sell	239,232 -100,000	-29%	-$10.6M	0.56%	34
2018 Q2	$28.5M	Hold	339,232	–	–	0.31%	43
2018 Q1	$20.9M	Hold	339,232	–	–	0.19%	51
2017 Q4	$19.8M	Hold	339,232	–	–	0.16%	57
2017 Q3	$19.7M	Sell	339,232 -50,000	-13%	-$5.39M	0.17%	57
2017 Q2	$47.1M	Buy	389,232 +25,000	+7%	+$2.9M	0.35%	54
2017 Q1	$41.2M	Sell	364,232 -100,000	-22%	-$11.7M	0.38%	47
2016 Q4	$50.4M	Buy	464,232 +185,000	+66%	+$22M	0.42%	54
2016 Q3	$46M	Sell	279,232 -229,000	-45%	-$36.1M	0.43%	47
2016 Q2	$72.5M	Buy	508,232 +267,840	+111%	+$39.1M	0.63%	41
2016 Q1	$30.9M	Buy	240,392 +50,166	+26%	+$5.92M	0.29%	49
2015 Q4	$28.4M	Buy	190,226 +96,300	+103%	+$16.3M	0.24%	53
2015 Q3	$15.6M	Buy	93,926 +74,500	+384%	+$16.4M	0.14%	63
2015 Q2	$4.69M	Hold	19,426	–	–	0.04%	73
2015 Q1	$5.48M	Buy	+19,426	New	+$4.21M	0.05%	69

Other funds holding ICPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Highfields Capital Management's ICPT Position: Q4 2018 in Review

Highfields Capital Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2018, closing a stake of 239,232 shares — an estimated $30.2M sold.

Highfields Capital Management first reported a position in ICPT in Q1 2015 and held it in 15 quarters. The position peaked at $72.5M in Q2 2016. 191 funds tracked by Wall St. Rank hold ICPT as of Q4 2018.

Highfields Capital Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
Highfields Capital Management sold 239,232 Intercept Pharmaceuticals, Inc. shares in Q4 2018, an estimated $30.2M.
Highfields Capital Management first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2015 and held it in 15 quarters.
Highfields Capital Management's Intercept Pharmaceuticals, Inc. position peaked at $72.5M in Q2 2016.
191 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2018.

Based on Highfields Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.